David A. Siegel Biotechnology

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
ADMA Adma Biologics, Inc.	$3.48B	$89 Million 0.22% of portfolio	4,454,400	Q3 2024 Reduced 4.3%
RPRX Royalty Pharma PLC	$11B	$85.8 Million 0.21% of portfolio	3,033,200	Q3 2024 Added 44.69%
RARE Ultragenyx Pharmaceutical Inc.	$3.07B	$54.9 Million 0.13% of portfolio	987,800	Q3 2024 Added 123.38%
IONS Ionis Pharmaceuticals Inc	$5.12B	$53.4 Million 0.13% of portfolio	1,332,411	Q3 2024 Added 3.52%
EXEL Exelixis, Inc.	$10.8B	$44.2 Million 0.11% of portfolio	1,702,590	Q3 2024 Added 6.11%
MRUS Merus N.V.	$1.95B	$36.5 Million 0.09% of portfolio	729,800	Q3 2024 Reduced 10.76%
INSM Insmed Inc	$9.56B	$28.7 Million 0.07% of portfolio	392,700	Q3 2024 Added 32.94%
ALNY Alnylam Pharmaceuticals, Inc.	$29.8B	$28.4 Million 0.07% of portfolio	103,100	Q3 2024 Reduced 60.15%
NVAX Novavax Inc	$676M	$25.3 Million 0.06% of portfolio	1,999,400	Q3 2024 Added 48.93%
MRNA Moderna, Inc.	$15.5B	$23.8 Million 0.06% of portfolio	356,500	Q3 2024 New
IMCR Immunocore Holdings PLC	$1.24B	$23.6 Million 0.06% of portfolio	757,700	Q3 2024 Added 65.62%
CORT Corcept Therapeutics Inc	$5.45B	$21.1 Million 0.05% of portfolio	457,100	Q3 2024 Reduced 11.24%
NTLA Intellia Therapeutics, Inc.	$920M	$21.1 Million 0.05% of portfolio	1,027,617	Q3 2024 Added 33.47%
MNKD Mannkind Corp	$1.81B	$16.6 Million 0.04% of portfolio	2,648,327	Q3 2024 Added 60.73%
BCRX Biocryst Pharmaceuticals Inc	$1.45B	$16.6 Million 0.04% of portfolio	2,181,012	Q3 2024 Added 13.62%
NVO Novo Nordisk A S	$200B	$16.2 Million 0.04% of portfolio	136,400	Q3 2024 Reduced 14.16%
SRPT Sarepta Therapeutics, Inc.	$10.6B	$16 Million 0.04% of portfolio	128,034	Q3 2024 Reduced 78.9%
PTCT Ptc Therapeutics, Inc.	$3.26B	$15.9 Million 0.04% of portfolio	429,842	Q3 2024 Added 10.35%
KYMR Kymera Therapeutics, Inc.	$2.23B	$15.9 Million 0.04% of portfolio	336,300	Q3 2024 Reduced 8.37%
NUVL Nuvalent, Inc.	$3.6B	$15.6 Million 0.04% of portfolio	152,200	Q3 2024 Reduced 5.58%
GMAB Genmab A/S	$13.7B	$15 Million 0.04% of portfolio	615,100	Q3 2024 Added 84.05%
IDYA Ideaya Biosciences, Inc.	$1.22B	$14.8 Million 0.04% of portfolio	468,100	Q3 2024 Added 1.67%
VRTX Vertex Pharmaceuticals Inc	$104B	$13.7 Million 0.03% of portfolio	29,400	Q3 2024 Reduced 82.89%
SNDX Syndax Pharmaceuticals Inc	$753M	$12.9 Million 0.03% of portfolio	669,352	Q3 2024 Added 7.74%
BMRN Biomarin Pharmaceutical Inc	$12.3B	$12.7 Million 0.03% of portfolio	181,314	Q3 2024 Reduced 21.82%
JAZZ Jazz Pharmaceuticals PLC	$7.79B	$11.8 Million 0.03% of portfolio	106,000	Q3 2024 Added 393.02%
XNCR Xencor Inc	$1.47B	$11.5 Million 0.03% of portfolio	572,900	Q3 2024 Reduced 1.31%
CYTK Cytokinetics Inc	$4.61B	$11.3 Million 0.03% of portfolio	214,700	Q3 2024 New
XENE Xenon Pharmaceuticals Inc.	$2.37B	$10.8 Million 0.03% of portfolio	273,700	Q3 2024 Added 31.02%
VRDN Viridian Therapeutics, Inc.\De	$785M	$10.1 Million 0.02% of portfolio	444,800	Q3 2024 Reduced 15.55%
TVTX Travere Therapeutics, Inc.	$1.1B	$10.1 Million 0.02% of portfolio	720,400	Q3 2024 Added 30.2%
CDMO Avid Bioservices, Inc.	$763M	$8.83 Million 0.02% of portfolio	776,050	Q3 2024 Added 28.73%
TARS Tarsus Pharmaceuticals, Inc.	$1.45B	$8.43 Million 0.02% of portfolio	256,400	Q3 2024 Reduced 16.64%
MIRM Mirum Pharmaceuticals, Inc.	$1.53B	$8.01 Million 0.02% of portfolio	205,500	Q3 2024 Added 14.23%
ACAD Acadia Pharmaceuticals Inc	$2.78B	$7.45 Million 0.02% of portfolio	484,300	Q3 2024 Added 774.19%
INVA Innoviva, Inc.	$1.24B	$7.3 Million 0.02% of portfolio	378,300	Q3 2024 Added 5.91%
ASND Ascendis Pharma A/S	$7.8B	$7.06 Million 0.02% of portfolio	47,258	Q3 2024 Reduced 76.6%
ALLO Allogene Therapeutics, Inc.	$280M	$6.75 Million 0.02% of portfolio	2,410,400	Q3 2024 Added 7.49%
CCCC C4 Therapeutics, Inc.	$199M	$6.07 Million 0.01% of portfolio	1,065,500	Q3 2024 Reduced 23.45%
ABCL Ab Cellera Biologics Inc.	$833M	$5.64 Million 0.01% of portfolio	2,177,600	Q3 2024 Added 23.39%
ARVN Arvinas, Inc.	$958M	$5.61 Million 0.01% of portfolio	227,600	Q3 2024 Added 445.8%
MRVI Maravai Lifesciences Holdings, Inc.	$675M	$5.56 Million 0.01% of portfolio	669,500	Q3 2024 Reduced 30.17%
TGTX Tg Therapeutics, Inc.	$4.69B	$5.27 Million 0.01% of portfolio	225,500	Q3 2024 Added 35.76%
SRRK Scholar Rock Holding Corp	$2.27B	$4.74 Million 0.01% of portfolio	592,000	Q3 2024 Added 0.2%
UTHR United Therapeutics Corp	$16.6B	$4.69 Million 0.01% of portfolio	13,101	Q3 2024 Reduced 7.75%
RLAY Relay Therapeutics, Inc.	$522M	$4.35 Million 0.01% of portfolio	614,200	Q3 2024 Added 44.59%
ZNTL Zentalis Pharmaceuticals, Inc.	$181M	$4.22 Million 0.01% of portfolio	1,149,400	Q3 2024 Added 44.23%
EDIT Editas Medicine, Inc.	$85.9M	$3.85 Million 0.01% of portfolio	1,129,000	Q3 2024 Added 31.82%
RNA Avidity Biosciences, Inc.	$1.65B	$3.76 Million 0.01% of portfolio	81,900	Q3 2024 Reduced 67.16%
QURE Uni Qure N.V.	$814M	$3.68 Million 0.01% of portfolio	746,500	Q3 2024 Added 247.69%

Shares Options

David A. Siegel

David A. Siegel is the co-founder and CEO of Two Sigma Advisers, a successful investment firm that uses technology and data-driven approaches to investing. Siegel is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track David A. Siegel's portfolio

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account